Clinical Trial Update: EARNEST Rifabutin Pharmacokinetics (PK) Substudy [Phase 2]

View source ↗

Summary

An update on the rifabutin pharmacokinetics substudy of the EARNEST trial (Phase 2) in HIV and tuberculosis, with results not yet reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Tuberculosis

Drugs mentioned

• Mycobutin (rifabutin)

Snippet

Sponsor: Justine Boles | Conditions: HIV, Tuberculosis | Phase 2 | Status: UNKNOWN